Each year 120,000 cases of non-small-cell lung cancer (NSCLC) are diagnosed in the US. While the majority of patients with this disease present in relatively advanced stages, 25-30% will have early-stage disease, i.e. confined to the parenchyma of a single lobe of one lung.
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Unfortunately, a significant number of patients with early-stage NSCLC are afflicted with underlying pulmonary or cardiovascular disease, which can be sufficiently severe to exclude them from surgery. In these circumstances definitive treatment becomes more challenging. Traditionally, radiotherapy has been used to treat these patients. However, radiation treatments using older techniques-especially those that rely upon 2-dimensional (2-D) treatment planning-are of limited effectiveness, with five-year survival around 20-30%. [2] [3] [4] There are several reasons why these disappointing results are not unexpected. First, patients treated with definitive radiation have a lower overall performance status than their surgical counterparts by virtue of the comorbidities that rendered them inoperable. Second, the doses of radiation used to treat these patients are now recognized to yield only a modest rate of tumor control. Understandably, clinicians had legitimate concerns about normal tissue toxicity, and limited doses accordingly. Third, the treatment margins used to encompass a lung tumor were generous, having to account for a) tissue at risk from microscopic tumor extension, b) tumor motion within the respiratory cycle, and c) set-up error.
These limitations were widely recognized and led to several avenues of investigation in an attempt to address them. At Karolinska Hospital in Sweden, Lax and Blomgren began investigations into the stereotactic body frame as a means of targeting tumors more precisely. 5 This concept was derived from the stereotactic head frame developed by Lars Leksell at the same institution some 40 years earlier. 6 The initial report of this extra-cranial, high-dose-per-fraction technique demonstrated a major response in nearly half of the 31 patients treated, including five of the six patients with lung tumors.
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This represented an advance over conventional 2-D treatment, using computed tomography (CT)-based three-dimensional (3-D) treatment planning, and delivering the treatments using 5-7 non-coplanar beams. This creates a more favorable dose profile in the irradiated normal tissue, sparing the majority of this tissue from doses that may result in clinical complications.
With the advent of intensity-modulated radiotherapy (IMRT), these treatments were further refined by the inverse planning method, which involves the assignment of dose parameters to both the tumor and nearby critical structures using a computer-driven iterative process to arrive at an optimized beam arrangement. This is, in essence, the technique that is widely applied today when administering stereotactic body radiotherapy (SBRT) for early-stage NSCLC. Recent clinical reports of patients treated with SBRT for medically inoperable NSCLC demonstrate promising results, with two-year survival rates of 60-80%
and local control rates of 80-90%. [7] [8] [9] [10] [11] While these advances in treatment techniques are promising, they fail to address several fundamental limitations. Foremost among these is the failure of both conventional CT-based treatment planning and port film verification systems to provide an accurate representation of tumor location, given the tumor motion that is inherent in the respiratory cycle.
These separate intrinsic errors of 1) target delineation and 2) target verification are both compounded and magnified when delivering highdose, hypofractionated treatments. This is because unintended Image-guided Radiotherapy for Early-stage Medically Inoperable Non-small-cell Lung Cancer To afford appropriate resolution for diagnostic purposes, PET scans require 35-45 minutes to complete. During this time patients are free-breathing at normal tidal volumes, which creates a motion artifact not unlike that which is observed in a slow CT scan. In the treatment planning process for SBRT, this is a property that can be exploited to generate a de facto 'motion envelope,' in which the maximal extent of tumor hysteresis is defined by the attenuated edges of the FDG avid mass.
One disadvantage of stand-alone FDG-PET imaging is the lack of useful anatomical information derived from the study. For this reason, FDG-PET is nearly always fused with an imaging study with good anatomical resolution-usually CT. The use of integrated PET/CT scans for treatment planning purposes in lung cancer is well characterized in the literature. 18, 19 The motion artifact generated during a PET scan can be used in the same fashion as the slow CT images mentioned above, facilitating generation of set has the potential to reduce the volume of lung receiving significant doses of radiation. 21 This reduction in volume can be further improved by the restriction of respiratory excursion provided by use of a stereotactic body frame 22 or body fixation mold. 23 At the University of Wisconsin, all patients receiving SBRT undergo 4-D-CT treatment planning scans. This has resulted in uniformly low mean residual lung doses, and a similarly low rate of clinically significant chronic treatment-related side effects (unpublished data).
Target Verification
Once an SBRT plan is generated, the next challenge is the delivery of this treatment with a high degree of accuracy. Conventional portal imaging, which relies upon alignment of bony anatomy between the daily film and the digitally reconstructed radiograph (DRR), is now recognized to be a poor surrogate for tumor localization. 24 
Conclusion
The use of image-guided SBRT for early-stage medically inoperable NSCLC has generated encouraging clinical results, and its use is becoming more widespread throughout the radiation oncology community. The integration of IGRT into the treatment planning and delivery process should be considered a necessary step to ensure highquality treatment, and to minimize the risk of associated treatmentrelated toxicities. ■
